Another biotech buy for Roche

After making a $43.7 billion offer linkurl:yesterday;http://www.the-scientist.com/blog/display/54841/ (July 21) to buy the 44% of Genentech stock it didn't already own, the Swiss pharmaceutical company announced another biotech purchase today. Roche will acquire linkurl:Mirus Bio Corporation;http://www.mirusbio.com/ for $125 million. Roche's half-year financial linkurl:results,;http://www.roche.com/home/figures/fig_halfyearrep_2008.htm released on Monday but eclipsed by the Genentech offer,

By | July 22, 2008

After making a $43.7 billion offer linkurl:yesterday;http://www.the-scientist.com/blog/display/54841/ (July 21) to buy the 44% of Genentech stock it didn't already own, the Swiss pharmaceutical company announced another biotech purchase today. Roche will acquire linkurl:Mirus Bio Corporation;http://www.mirusbio.com/ for $125 million. Roche's half-year financial linkurl:results,;http://www.roche.com/home/figures/fig_halfyearrep_2008.htm released on Monday but eclipsed by the Genentech offer, showed a six percent decline in pharmaceutical sales. Roche intends to borrow half the funds required for the Genentech takeover, according to a report published Monday by Global Insight pharmaceutical analyst Gaelle Marinoni, which "implies that the Swiss giant is keeping its options and cash stash open for further smaller acquisitions." Mirus, one of those smaller acquisitions, is a private US-owned company based in Madison, Wisconsin that specializes in RNA interference (RNAi) technologies. Their products include nucleic acid reagents, kits, and protocols, and the company has siRNA delivery platforms in the pipeline. This is not Roche's first move toward linkurl:RNAi;http://www.the-scientist.com/article/display/18847/ therapeutics: last year, Roche struck a deal linkurl:Alnylam Pharmaceuticals Inc.,;http://www.the-scientist.com/blog/display/54395/ a German company, for the rights to their RNAi technology, an alliance the companies claimed to be worth $1 billion. "The race is on" for successful use of the RNAi technology, according to a Global Insight analysis, "and any breakthrough could prove very lucrative." Roche plans to maintain Mirus's research station in Madison. The takeover is scheduled to be completed by the end of the year. Meanwhile, Genentech and Roche leaders met today to informally discuss the buyout, but some analysts are expecting that Roche will to have to increase its offer to take over the biotech giant. The offer is at $89 a share, but Genentech stock jumped to $92.91 by the end of the day on Monday, a possible sign that investors expect a raise on the offer, according to linkurl:the Associated Press.;http://www.iht.com/articles/ap/2008/07/22/business/EU-Switzerland-Roche-Genentech.php

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech